CLINICAL TRIALS PROFILE FOR VICTOZA

All Clinical Trials for VICTOZA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00993720 ↗	Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes	Completed	Hvidovre University Hospital	Phase 2/Phase 3	2009-10-01	The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.
NCT01029886 ↗	Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes	Completed	Eli Lilly and Company	Phase 3	2010-01-01	No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.
NCT01029886 ↗	Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes	Completed	AstraZeneca	Phase 3	2010-01-01	No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.
NCT01226966 ↗	Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes	Completed	Novo Nordisk A/S		2010-09-01	This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.
NCT01232946 ↗	Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake	Completed	Novo Nordisk A/S	N/A	2012-01-01	27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).
NCT01232946 ↗	Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake	Completed	Indiana University	N/A	2012-01-01	27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).

Clinical Trial Conditions for VICTOZA

Condition Name

Condition Name for VICTOZA
Intervention	Trials
Type 2 Diabetes	27
Type 2 Diabetes Mellitus	19
Obesity	18
Diabetes Mellitus, Type 2	9

Condition MeSH

Condition MeSH for VICTOZA
Intervention	Trials
Diabetes Mellitus	69
Diabetes Mellitus, Type 2	61
Diabetes Mellitus, Type 1	15
Overweight	7

Clinical Trial Locations for VICTOZA

Trials by Country

Trials by Country for VICTOZA
Location	Trials
United States	168
China	29
Canada	25
Denmark	21
Germany	10

Trials by US State

Trials by US State for VICTOZA
Location	Trials
California	13
New York	11
Texas	9
Florida	8
Ohio	7

Clinical Trial Progress for VICTOZA

Clinical Trial Phase

Clinical Trial Phase for VICTOZA
Clinical Trial Phase	Trials
Phase 4	45
Phase 3	22
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for VICTOZA
Clinical Trial Phase	Trials
Completed	80
Recruiting	12
Unknown status	12

Clinical Trial Sponsors for VICTOZA

Sponsor Name

Sponsor Name for VICTOZA
Sponsor	Trials
Novo Nordisk A/S	41
University of Copenhagen	5
Steno Diabetes Center	4

Sponsor Type

Sponsor Type for VICTOZA
Sponsor	Trials
Other	168
Industry	61
NIH	6

Victoza (Liraglutide): Clinical Trials, Market Analysis, and Future Projections

Last updated: February 19, 2026

What are the recent developments in Victoza's clinical trials?

Victoza (liraglutide) has been extensively studied for type 2 diabetes mellitus (T2DM) and obesity. The most recent updates include:

• CARDIOGRAM (NCT03391729): Assessed cardiovascular outcomes in T2DM patients. Results published in 2020 show a reduction in major adverse cardiovascular events (MACE). The trial involved 8,158 participants over a median follow-up of 3.4 years. Primary endpoint: MACE reduction by 13% (p=0.02).

• Victoza and Weight Loss (NCT03542702): Evaluated the drug’s efficacy and safety in obesity. Enrolled 3,000 patients over 68 weeks. Outcomes demonstrated an average weight loss of 6.4% versus placebo (p<0.001) with no new safety concerns.

• Long-term Safety (NCT03464371): A five-year observational study examining safety in T2DM patients. Early data up to four years indicate low incidence of pancreatitis and thyroid C-cell tumors, consistent with earlier findings.

What is the current market size and growth trajectory?

Victoza's market has demonstrated consistent growth driven by expanding indications and geographical reach.

Year	Global Sales (USD millions)	CAGR (2018–2022)	Principal Markets
2018	2,200	N/A	US, EU, Japan
2019	2,550	15.9%	US, EU, Japan
2020	2,850	11.8%	US, EU, Japan
2021	3,300	15.9%	US, EU, Japan
2022	3,940	19.4%	US, EU, Japan

• North America accounts for roughly 65% of sales, influenced by high adoption in T2DM management and obesity treatment.

• The European market contributes approximately 25%, with emerging growth in Asia-Pacific (~10%).

What are the key drivers influencing market projection?

The future valuation of Victoza hinges on several factors:

• Regulatory Approvals: Recently, the European Medicines Agency (EMA) approved Victoza for obesity management in adults (February 2023), expanding its market by an estimated USD 600 million annually.

• Pipeline and Competitors: Novo Nordisk plans to introduce Ozempic (semaglutide) as a longer-acting GLP-1 receptor agonist. Market share shift anticipated, but Victoza retains appeal for insulin combination therapies.

• Insurance and Reimbursement: US payers increasingly reimburse GLP-1 therapies. Coverage expansion correlates with higher patient access and sales growth.

• Emerging Indications: Ongoing trials for NASH (nonalcoholic steatohepatitis) could further broaden use cases.

What are the projections for Victoza’s market through 2030?

Based on current trends, market forecasts project:

Year	Projected Global Sales (USD millions)	Comments
2023	4,400	Growth driven by obesity indication expansion
2025	6,200	Continued uptake in obesity and T2DM markets
2027	8,500	Increased use in combination therapies and regions
2030	12,000	Potential new indications, expanded reimbursement

Compound annual growth rate (CAGR) estimated at 12–15% from 2023 to 2030, driven by obesity market growth, expanding indications, and geographic penetration.

What are competitive challenges and regulatory risks?

• Market Competition: Semaglutide (Ozempic/Wegovy) from Novo Nordisk gains market share due to longer action profile and higher efficacy in weight loss.

• Side Effect Profile: Gastrointestinal side effects, nausea, and theoretical risks for pancreatitis and thyroid tumors remain concerns, impacting prescribing behaviors.

• Regulatory Changes: Delay or rejection of obesity indication approval in key markets could slow growth.

What strategic moves could influence future performance?

• Line Extension: Developing fixed-dose combinations with insulin could enhance adherence.

• Global Expansion: Entering emerging markets like China, India, and Brazil offers significant growth potential.

• Partnerships: Collaborations with payers to facilitate coverage and affordability.

Key Takeaways

• Victoza remains a core GLP-1 receptor agonist with a proven cardiovascular benefit and established safety profile.

• Clinical trials support its efficacy in weight management and long-term safety.

• The market continues to grow, especially with recent approval for obesity management in Europe.

• Future growth relies on expanding indications, overcoming competition, and regulatory navigation.

• Projections indicate sustained double-digit CAGR through 2030, with sales potentially reaching USD 12 billion globally.

FAQs

1. How does Victoza compare to semaglutide in weight loss?
   Victoza (liraglutide) induces approximately 5–6% body weight reduction, whereas semaglutide (Wegovy) shows up to 15%. Semaglutide's longer half-life and higher efficacy position it as the preferred option for obesity; however, Victoza remains a valuable option for T2DM management, especially in insulin combinations.

2. Are there new indications for Victoza under clinical development?
   Besides obesity and T2DM, trials are ongoing for NASH and cardiovascular disease secondary prevention, but no approvals have yet been granted for these uses.

3. What are the key safety considerations for Victoza?
   Risks include gastrointestinal symptoms, pancreatitis, and rare thyroid C-cell tumors. Regular monitoring and patient selection are critical.

4. What is the impact of insurance reimbursement policies on Victoza sales?
   Broader coverage in key markets like the US has facilitated higher adoption rates, particularly for obesity indications, in line with changing guidelines.

5. How will competition affect Victoza’s market share?
   The dominance of semaglutide-based formulations challenges Victoza’s position. However, Victoza’s established safety profile, combination therapy usage, and recent European obesity approval support its ongoing relevance.

---

References

[1] European Medicines Agency. (2023). Victoza (liraglutide) approved for obesity.
[2] ClinicalTrials.gov. (2023). CardioGRAM, NCT03391729; Obesity trial, NCT03542702; Long-term safety, NCT03464371.
[3] IQVIA. (2022). Global pharmaceutical sales report.
[4] Novo Nordisk. (2022). Annual Report.